For millions of women navigating chronic pelvic pain, heavy bleeding, or unexplained infertility, the path to a diagnosis can be a years-long odyssey of specialist visits, dismissed symptoms, and inconclusive tests. Womb WatchAI, a Brooklyn-based biotech startup founded in 2024, is building an AI platform with an ambitious goal: to shorten that journey by decoding the complex biological signatures of conditions that often go unseen. The company’s core bet is that a proprietary AI system, trained exclusively on female biological data, can recognize patterns and risks long before traditional clinical pathways catch up.
Its flagship product, Rhythm by Womb WatchAI, is an app and digital twin platform that allows users to track symptoms, nutrition, mood, and cycle data [rhythmbywombwatchai.com, retrieved 2026]. The underlying engine, which the company calls the Bio-Intent Orchestration System (BIOS), is designed to analyze what it claims are over 64,000 biological variables [WOMEN OF WEARABLES, retrieved 2024]. Founder and CTO Quanda Francis, who holds multiple patent-pending technologies in the space, describes BIOS as a foundational intelligence layer built to personalize, predict, and optimize women’s health [WOMEN OF WEARABLES, retrieved 2024]. The company has filed six provisional patents and secured a USPTO trademark as it works to translate this technical architecture into clinical utility [Instagram, retrieved 2024].
The Architecture of a Digital Twin
At the heart of Womb WatchAI’s approach is a focus on creating a comprehensive digital biomarker profile. The platform integrates with Apple Health and Google Health, pulling in data across five stated areas of analysis: period tracking, nutrition, lab results, menstrual flow, and cancer surveillance [Womb WatchAI, retrieved 2024]. The company says it has developed six proprietary AI models trained solely on female data to power this analysis [Womb WatchAI, retrieved 2024]. This data-centric, model-driven approach is intended to move beyond simple cycle tracking into the realm of predictive health, with a stated focus on conditions like endometriosis, polycystic ovary syndrome (PCOS), uterine fibroids, and adenomyosis [Womb WatchAI, retrieved 2024].
The company’s early-stage traction is signaled through program affiliations rather than commercial deployments. It is a member of the NVIDIA Inception program and has backing from Google for Startups, typical of early technical validation for AI-focused health companies [NVIDIA Inception Program]. Founder Quanda Francis has stated she is personally funding the venture, underscoring its bootstrap phase [Instagram, retrieved 2024]. In 2025, the company launched the "Her Health, Her Future" Research Fund, an initiative aimed at directing resources and gathering questionnaire data to further investigate women’s biology [EIN Presswire].
Navigating a Crowded and Complex Field
The ambition to bring order to women’s health data places Womb WatchAI in a competitive landscape with several distinct approaches. The company must differentiate its AI-driven diagnostic ambition from more established tracking apps and a new wave of clinical research tools.
| Company | Primary Focus | Key Differentiation |
|---|---|---|
| Womb WatchAI | AI-powered digital twin & biomarker analysis | Proprietary BIOS™ engine, 6 female-data-only models, cancer surveillance claims |
| Owaves | Circadian rhythm & daily planning | Time-based lifestyle optimization, not disease-specific |
| Crescent Health | Fertility & cycle tracking | Focus on conception and pregnancy planning |
| Chorus | Clinical research platform | Connects patients with relevant clinical trials |
| MindMics | Cardiovascular analytics via earphones | Uses infrasonic hemodynamic sensing, a different biomarker modality |
For Womb WatchAI, the path to clinical adoption and revenue is its most significant unanswered question. The company operates on a B2B2C model, but has not yet publicly named healthcare system partners, insurer contracts, or validated clinical studies for its predictive claims. The regulatory pathway for an AI system making health risk predictions is also formidable; such software typically falls under FDA scrutiny as a Software as a Medical Device (SaMD), a process the company has not discussed publicly. Furthermore, while the claim of a 56,000% organic growth rate circulates on social channels, it remains unverified by standard metrics like monthly active users or paid subscriptions [Instagram, retrieved 2024].
The company’s potential rests on a few critical, unproven assumptions. Its technical differentiation hinges on the unique predictive power of its BIOS engine and its curated dataset. Without peer-reviewed validation or clear clinical outcomes data, it remains a compelling prototype in a field that rightly demands evidence. The founder’s deep technical conviction is clear, but the next phase requires translating that vision into partnerships with clinical researchers who can help test and refine the models in real-world patient populations.
The Standard of Care Today
For the patient population Womb WatchAI aims to serve,those with complex, chronic gynecological conditions,the current standard of care is often fragmented and delayed. Diagnosis for conditions like endometriosis, which affects an estimated one in ten women, frequently takes seven to ten years. It relies on a slow process of symptom diaries, pelvic exams, imaging like ultrasounds or MRIs, and often definitive laparoscopic surgery. For PCOS, diagnosis is based on a consensus of symptoms, blood tests for hormone levels, and ultrasound findings. This process is not only slow but subjective, varying greatly by provider experience and patient access to specialists. Womb WatchAI’s entire thesis is that continuous, AI-mediated analysis of multimodal personal data can surface objective patterns and risk flags much earlier, potentially guiding patients to the right specialist with a richer data profile in hand. It is a humane and urgent goal, even if the technological path to achieving it is steep.
Sources
- [rhythmbywombwatchai.com, retrieved 2026] Rhythm by Womb WatchAI product page | https://www.rhythmbywombwatchai.com
- [WOMEN OF WEARABLES, retrieved 2024] WoW Woman in BioTech - Quanda Francis, founder and Chief Technology Officer of Womb WatchAI | https://www.womenofwearables.com/new-blog/wow-woman-in-biotech-quanda-francis-founder-and-chief-technology-officer-of-womb-watchai
- [Womb WatchAI, retrieved 2024] Company website and product claims | https://www.wombwatchai.com
- [Instagram, retrieved 2024] Womb WatchAI official Instagram account | https://www.instagram.com/wombwatchai/
- [NVIDIA Inception Program] NVIDIA Inception program for AI startups | https://www.nvidia.com/en-us/startups/
- [EIN Presswire, 2025] Her Health, Her Future Research Fund announcement | https://www.einpresswire.com/article/704199591
- [LinkedIn, retrieved 2024] Quanda Francis profile | https://www.linkedin.com/in/quandafrancis